UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 83-1281555 | | --- | --- | | ( State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) ...

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Corporate Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President and Chief Executive Officer Ian Clements - Chief Financial Officer Peter Radovich - Chief Operating Officer Pamela Vig - Head of R&D Conference Call Participants Jessica Fye - JPMorgan Mani Foroohar - SVB Securities Josh Schimmer - Evercore Ryan Deschner - Raymond James David Lebowitz - Citi Brian Skorney ...

Financial Transactions and Revenue - The company received $50.0 million upon closing of the RIPA and an additional $65.0 million in April 2021, totaling $115.0 million[349]. - Revenue Interest Payments to Purchasers will be tiered based on annual net sales of Livmarli, starting at 9.75% for sales up to $350.0 million and 2.00% for sales exceeding $350.0 million[349]. - If Purchasers receive Revenue Interest Payments equal to or greater than 110.0% of total payments by December 31, 2026, the Revenue Interests will be reduced to 2.00% at Tier 1 and 0.00% at Tier 3 starting January 1, 2027[349]. - The Purchasers' rights to Revenue Interest Payments will terminate once they receive 195.0% of the Cumulative Purchaser Payments, unless the RIPA is terminated earlier[350]. - The company may face increased cash outflows due to payment requirements under the RIPA, impacting future operations and capital expenditures[350]. Intellectual Property and Patent Risks - The company must maintain sufficient intellectual property protection for Livmarli and its product candidates to prevent competitors from commercializing similar products[351]. - The patent application process is complex and uncertain, with no guarantee that patents will be issued or enforced effectively[352]. - The company may face challenges in protecting its intellectual property due to potential changes in patent laws and competition from entities with greater resources[357]. - The company’s ability to commercialize Livmarli may be adversely affected if patents are deemed invalid or if competitors develop similar technologies[360]. - The company relies on method-of-use and formulation patents to protect Livmarli and volixibat, with no composition-of-matter patents for maralixibat[367]. - The company faces uncertainties in patent law due to the America Invents Act, which could increase costs and affect patent enforcement[365]. - The company has rights to patents and applications in the U.S., Europe, and other jurisdictions for treating cholestatic liver diseases, but patent applications may not always issue as patents[367]. - Compliance with procedural requirements for patent protection is critical, as non-compliance could lead to abandonment or loss of patent rights[371]. - The company may struggle to protect intellectual property rights globally, as enforcement varies significantly across jurisdictions[374]. - Changes in U.S. patent law could diminish the value of patents, impacting the company's ability to protect its products[372]. - The company is subject to potential claims challenging the inventorship or ownership of its patents, which could result in loss of valuable intellectual property rights[382]. - The company has licensing agreements with third parties, such as Pfizer and Sanofi, which are crucial for its business and require compliance with various obligations[380]. - The implementation of the European Unified Patent Court may create uncertainties regarding the enforcement of patent rights in Europe[378]. - Geopolitical actions, such as those related to the conflict in Ukraine, could hinder the company's ability to maintain patent rights in affected regions like Russia[377]. - The company has a licensing agreement with Sanofi for intellectual property rights related to volixibat, which may require additional proprietary rights from third parties for business growth[385]. - The company collaborates with U.S. and foreign academic institutions to accelerate preclinical research, but may face challenges in negotiating exclusive licenses for resulting proprietary rights[388]. - The competitive landscape for acquiring third-party proprietary rights is challenging, as more established companies may have greater resources and capabilities[387]. - The company may face significant royalty obligations for future products, which could impact profitability if successful commercialization is achieved[386]. - There is a risk of third-party claims alleging intellectual property infringement, which could delay drug discovery and development efforts[390]. - The company may not be aware of existing patents that could be infringed by its products, potentially leading to legal challenges[392]. - Patent litigation is costly and time-consuming, and the company may not have sufficient resources to defend against such claims effectively[400]. - If a third party prevails in a patent infringement lawsuit, the company may have to stop selling infringing products and pay substantial damages[401]. - The company may need to obtain licenses from third parties to advance research or commercialize products, which may not be available on reasonable terms[402]. - The company may face claims related to the wrongful hiring of employees from competitors, which could lead to litigation and distract management[403]. Stock and Market Risks - The closing price of the company's common stock ranged from a low of $15.50 to a high of $29.44 from January 1, 2022, to March 7, 2023[420]. - The company faces risks related to the adoption of Livmarli by physicians and patients, which is necessary for commercial success[421]. - The company has not declared or paid any cash dividends on its common stock and anticipates retaining future earnings for business development[424]. - The company’s stock price may be highly volatile due to various factors, including regulatory approvals and market conditions[420]. - Significant stockholders and management own a substantial percentage of the company's stock, allowing them to exert considerable control over matters requiring stockholder approval[425]. - The company may need significant additional capital for future operations, including clinical trials and commercialization efforts, potentially leading to dilution of existing stockholders' ownership[427]. - As of December 31, 2022, the remaining capacity under the Sales Agreement for issuing common stock is approximately $46.3 million[427]. - The 2019 Equity Incentive Plan allows for an automatic increase in shares reserved for issuance by 5.0% annually until January 1, 2029, which may lead to further dilution for stockholders[429]. - The company has provisions that could delay or prevent a change of control, potentially impacting the market price of its common stock[434]. - The company is subject to Nasdaq's continued listing requirements, and failure to meet these could result in delisting, negatively affecting stock price and liquidity[433]. Operational and Compliance Risks - Cybersecurity risks are a significant concern, with potential threats from various sources, including organized crime and nation-state actors, which could disrupt operations and harm reputation[441]. - Future business transactions may expose the company to additional cybersecurity vulnerabilities, complicating integration efforts[442]. - The company has adopted exclusive forum provisions that may limit stockholders' ability to bring claims in favorable jurisdictions, potentially increasing litigation costs[439]. - Activist stockholder actions could adversely affect the company's operating results and financial condition, leading to increased costs and distractions for management[432]. - The company relies on third-party service providers for critical business systems, which poses risks related to information security and potential adverse consequences from security incidents[444]. - Increased frequency and severity of supply-chain attacks could compromise the company's information technology systems and those of third-party partners[446]. - The company may incur significant costs related to compliance with data privacy and security obligations, including potential government enforcement actions and litigation[447]. - The company is subject to U.S. and foreign export and import controls, which could impair its ability to compete and result in serious legal consequences for violations[451]. - The company has incurred and will continue to incur significant costs as a result of operating as a public company, impacting its financial condition and results of operations[461]. - Compliance with the Sarbanes-Oxley Act and other regulations may divert management's attention and increase operational costs, potentially affecting net income[462]. - The company may face challenges in maintaining effective internal controls, which could impair the accuracy of financial statements and lead to sanctions[460]. - The company is classified as an emerging growth company, allowing it to take advantage of reduced reporting requirements until December 31, 2024, unless certain revenue thresholds are met[454]. - The company may discover weaknesses in its internal financial controls that could result in material misstatements of its consolidated financial statements[458]. Financial Condition and Market Environment - As of December 31, 2022, the company maintains cash, cash equivalents, and investments primarily in highly liquid and high-quality government and debt securities, with minimal exposure to interest rate risk due to the short-term nature of instruments in the portfolio[577]. - A hypothetical change in interest rates of 100 basis points is not expected to materially impact the fair market value of cash equivalents, restricted cash equivalents, and investments as of December 31, 2022[577]. - The company has entered into a RIPA, where the effective interest rate on the liability may vary based on actual and forecasted net product sales, impacting interest expense recognized each reporting period[578]. - Minimal assets and liabilities denominated in foreign currencies as of December 31, 2022, resulted in foreign currency exchange rate changes having no material impact on the company's financial condition or results of operations[579]. - Inflation has increased costs related to labor and clinical trials, but it is not believed to have significantly impacted the company's results of operations for the periods presented[580].

Corporate Presentation We use our website (www.mirumpharma.com), LinkedIn page (www.linkedin.com/company/mirum-pharmaceuticals), and Twitter account (https://twitter.com/mirumpharma) as channels of distribution of information about our company, product candidates, planned announcements, attendance at upcoming conferences and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors shou ...

Financial Data and Key Metrics Changes - Mirum Pharmaceuticals reported net sales of $47.2 million for LIVMARLI year-to-date, with an estimated $70 million in net product sales expected for 2022, indicating a strong first full year of approval [7][10] - The company raised its full-year net product sales guidance for LIVMARLI to $70 million, reflecting a 20% quarter-over-quarter growth from Q3 to Q4 [10][64] Business Line Data and Key Metrics Changes - LIVMARLI's net sales for Q3 2022 were $18.8 million, showing continued quarterly growth [10][11] - The company observed high levels of compliance and persistence with LIVMARLI, maintaining strong reimbursements [10] Market Data and Key Metrics Changes - Mirum received a positive CHMP opinion for LIVMARLI in Europe for the treatment of cholestatic pruritus and Alagille syndrome, with launches planned in key European countries in 2023 [8] - Over 130 Alagille patients outside the U.S. are currently receiving LIVMARLI through clinical and expanded access programs [13] Company Strategy and Development Direction - The company aims to expand its market presence internationally, with Germany set to be the first European country to launch LIVMARLI in Q1 2023 [12] - Mirum is focused on leveraging the positive results from the MARCH-PFIC Phase III study to support regulatory submissions and further market expansion [59] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the acceleration of new patient starts for LIVMARLI, attributing previous revenue growth deceleration to seasonal factors [64] - The management team highlighted the importance of ongoing clinical data and patient feedback in shaping future strategies and product offerings [59][90] Other Important Information - The MARCH-PFIC Phase III study enrolled 93 PFIC patients, marking it as the largest PFIC study conducted, with significant improvements observed in pruritus and serum bile acids [16][50] - The study results indicated that maralixibat could produce both biologically and clinically significant improvements, particularly in pruritus and serum bile acids across various PFIC types [50][52] Q&A Session Summary Question: Acceleration of new starts on LIVMARLI and revenue growth deceleration - Management noted an acceleration in new patient starts in the fall, which they believe will contribute to revenue growth despite summer softness due to seasonal factors [64] Question: Differences between LIVMARLI and Bylvay - Professor Thompson indicated that while both drugs show significant response rates, a direct head-to-head comparison has not been conducted, and individual patient factors will influence treatment decisions [65][66] Question: Patient dynamics and growth going forward - Management confirmed no significant changes in patient demographics, with consistent age and body weight among new patients [79] Question: Comparability with Bylvay and efficacy calculations - Management stated that while they cannot make definitive cross-study comparisons, their data shows consistent results across various measurement times [85] Question: Critical results from MARCH-PFIC for label adoption - Professor Thompson emphasized the importance of understanding the response rates and maintaining long-term responses in patients as critical for label adoption [95]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ Commission File Number: 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 83-12815 ...

Corporate Presentation September 2022 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our business strategy, objectives and opportunities. Forward- looking statements are subject to known and unknown risks, u ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Ian Clements - CFO Chris Peetz - President and CEO Peter Radovich - COO Pam Vig - Head, R&D Conference Call Participants Jessica Fye - JPMorgan Lili Nsongo - SVB Ed Arce - H.C. Wainright Ryan Deschner - Raymond James Operator Good afternoon. My name is Chris, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Mirum Q2 2022 Business Update. [Oper ...

WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ Commission File Number: 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 83-1281555 ( ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2022 was $12.9 million, including $10.9 million from net product revenue of LIVMARLI and $2 million in licensing revenue from a partner in China [22] - Operating expenses for the quarter totaled $45.6 million, with R&D expenses at $24.1 million and SG&A expenses at $19.1 million [23] - The company had cash, cash equivalents, and investments of $239.9 million at the end of Q1 2022 [23] Business Line Data and Key Metrics Changes - LIVMARLI generated net product revenue of $10.9 million in Q1 2022, reflecting strong demand dynamics and refill cadence [7][12] - Approximately 75% of expenses were reimbursed in Q1, with expectations for this rate to increase to 90% or higher in Q2 and beyond [12] Market Data and Key Metrics Changes - The payer mix for LIVMARLI currently stands at approximately 50% Medicaid and 50% commercial [12] - The company is preparing for international launches of LIVMARLI, with anticipated approval in Europe later in 2022 and early access programs being initiated [15] Company Strategy and Development Direction - Mirum Pharmaceuticals aims to capitalize on a greater-than-$500 million U.S. market opportunity in Alagille syndrome while progressing with five other late-stage clinical programs [9] - The company is focused on innovative research for rare diseases to expedite the development of new medicines [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth throughout the year, driven primarily by the U.S. market [28][40] - The company is optimistic about the potential for LIVMARLI to address unmet medical needs in Alagille syndrome and other cholestatic conditions [24] Other Important Information - The MARCH-PFIC Phase III clinical trial is fully enrolled, with top-line data expected in Q4 2022 [16] - The INDIGO Phase II data has been published, showing significant improvements in patient outcomes [19] Q&A Session Summary Question: What drove the strong revenue of $10.9 million? - Management noted strong demand dynamics and refill cadence, with expectations for continued growth above the previously stated floor of $50 million for the year [27][30] Question: What is the current status of drug reimbursement? - Management expects to achieve a reimbursement rate of 90% in Q2 and beyond [31] Question: How is the LIVMARLI launch progressing in the U.S.? - The conversion of expanded access patients to commercial product was rapid, and the company is seeing strong adoption among targeted key accounts [33] Question: What are the timelines for the European launch? - The first launch will be in Germany following EMA approval, with additional Western European countries targeted for 2023 [35][36] Question: How does the company plan to maintain brand awareness for LIVMARLI? - The focus will be on rolling out access for as many patients as possible and publishing data from the clinical program [45] Question: What is the expected R&D spend trend? - R&D spending is anticipated to remain flat throughout the year, with some studies winding down while others ramp up [42] Question: Is the company seeking collaborators for additional PFIC genetic subtypes? - The company is actively looking for opportunities to grow and develop underappreciated programs in pediatric rare diseases [73]